公开(公告)号：US20240361325A1

公开(公告)日：2024-10-31

申请号：US18765866

申请日：2024-07-08

Applicant: Albert Einstein College of Medicine

Inventor： John S. Condeelis ,  Allison S. Harney

IPC: G01N33/574 ,  C07K16/22

CPC classification number: G01N33/57484 ,  C07K16/22 ,  G01N33/574 ,  C07K2317/76 ,  G01N33/57415 ,  G01N2800/50 ,  G01N2800/52

Abstract: Disclosed are kits and methods for detecting the presence of tumor sites that are active in tumor cell dissemination and uses thereof for determining the risk of tumor cells undergoing hematogenous metastasis, for assessing the prognosis of a subject undergoing treatment for a localized tumor, for determining a course of treatment for a localized tumor, and for identifying agents to treat or prevent hematogenous metastasis.

公开(公告)号：US20240360510A1

公开(公告)日：2024-10-31

申请号：US18563450

申请日：2022-05-24

Applicant: UNIVERSITE PARIS-SACLAY ,  INSERM (Institut National de la Santé et de la Recherche Médicale) ,  ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ,  CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL

Inventor： Jérôme BOULIGAND ,  Isabelle Bourdeau ,  Fanny CHASSELOUP ,  André Lacroix ,  Peter KAMENICKÝ

IPC: C12Q1/6883 ,  A61K45/00 ,  G01N33/68

CPC classification number: C12Q1/6883 ,  A61K45/00 ,  G01N33/6893 ,  C12Q2600/156 ,  G01N2333/90274 ,  G01N2800/04 ,  G01N2800/50

Abstract: The present results show that KDM1A is a key epigenetic regulator of tissue-specific expression of GIP receptor and possibly of other receptors from the G-protein coupled receptor family in hormone-producing glands, and that its alteration leads to the development of aberrant overexpression of eutopic hormone receptors or expression of ectopic hormone receptors that lead to abnormal steroidogenesis. They also show that loss of expression of KDM1A is likely to be the initiating event that trigger the abnormal cell proliferation leading to the development of tissue lesions in adrenal and possibly in other endocrine tissues (notably in the adrenal glands). The present invention therefore proposes to detect altered expression of KDM1A in the genome of subjects, in order to diagnose a genetic predisposition to an endocrine disease and/or to an endocrine hyperplasia. On another hand, the present results suggest that the physiological eutopic GIP receptor expression in the pancreas may be also epigenetically regulated by KDM1A. This expression could be pharmacologically targeted by KDM1A inhibitors so as to treat patients suffering from diabetes mellitus and other metabolic diseases.

公开(公告)号：US20240345090A1

公开(公告)日：2024-10-17

申请号：US18580710

申请日：2022-07-19

Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED

Inventor： Malú Mariadelourdes Gámez TANSEY ,  Habibeh KHOSHBOUEI

IPC: G01N33/573 ,  A61K38/00 ,  C07K14/525 ,  G01N33/68

CPC classification number: G01N33/573 ,  C07K14/525 ,  G01N33/6854 ,  A61K38/00 ,  G01N2333/90245 ,  G01N2800/50

Abstract: Disclosed is a method for detecting a level of tyrosine hydroxy lase (TH) in a biosample from a subject. The biosample comprises a homogenate of peripheral monocytes from the subject. Detection involves conducting an ELISA on the biosample using a biotinylated anti-TH antibody under conditions to allow the biotinylated anti-TH antibody to bind to TH. If elevated TH is detected, an amount of a TNFα inhibitor effective to decrease TH in peripheral monocytes of the subject may be administered. In a particular method, a TNFα inhibitor is administered if the TH level in the biosample is higher than a threshold level.

公开(公告)号：US20240344140A1

公开(公告)日：2024-10-17

申请号：US18594650

申请日：2024-03-04

Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

Inventor： Hongzhi Zou ,  David Ahlquist ,  Jonathan J. Harrington

IPC: C12Q1/6886 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  G01N33/57419 ,  C12Q2600/154 ,  C12Q2600/156 ,  G01N2333/805 ,  G01N2800/50 ,  G01N2800/7028

Abstract: The present invention provides methods and materials related to the detection of colorectal neoplasm-specific markers in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals having a colorectal neoplasm by detecting the presence of exfoliated epithelial markers (e.g., human DNA, tumor associated gene alterations, tumor associated proteins) and blood markers (e.g., hemoglobin, serum proteins) in a stool sample obtained from the mammal.

公开(公告)号：US20240302367A1

公开(公告)日：2024-09-12

申请号：US18573224

申请日：2022-06-07

Applicant: The Johns Hopkins University ,  The Board of Trustees of the Leland Stanford Junior University

Inventor： Antony Rosen ,  Livia A. Casciola-Rosen ,  David Fiorentino

IPC: G01N33/564 ,  A61K39/00 ,  C07K16/18 ,  G01N33/574

CPC classification number: G01N33/564 ,  C07K16/18 ,  G01N33/57484 ,  A61K2039/505 ,  G01N2800/20 ,  G01N2800/50

Abstract: This document relates to materials and methods for assessing and/or treating mammals (e.g., humans having autoimmune diseases). For example, materials and methods for determining if a mammal (e.g., a human having an autoimmune disease) has one or more antibodies that can be used to identify the mammal as having a lower risk of cancer or as having a higher risk of cancer are provided. Materials and methods for treating a mammal (e.g., a human) identified as having a higher cancer risk for cancer are also provided.

公开(公告)号：US20240288444A1

公开(公告)日：2024-08-29

申请号：US18351151

申请日：2023-07-12

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Alfred Garfall ,  Alex Ganetsky ,  Saar Gill ,  Simon Lacey ,  Jan J. Melenhorst ,  David Teachey ,  Eric Lancaster ,  Adam David Cohen ,  Pamela Shaw

IPC: G01N33/68 ,  A61K31/675 ,  A61K35/17 ,  A61K39/395 ,  A61K45/06 ,  A61P29/00 ,  A61P37/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C12Q1/6876 ,  G01N33/50

CPC classification number: G01N33/6863 ,  A61K31/675 ,  A61K35/17 ,  A61K39/3955 ,  A61K45/06 ,  A61P29/00 ,  A61P37/00 ,  C07K14/7051 ,  C07K14/70578 ,  C07K16/2803 ,  C12Q1/6876 ,  G01N33/5047 ,  G01N33/6866 ,  G01N33/6869 ,  G01N33/6893 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/03 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N2800/24 ,  G01N2800/50 ,  G01N2800/52 ,  G01N2800/7095

Abstract: The present disclosure relates to the identification and use of biomarkers (e.g., analytes, analyte profiles, or markers (e.g., gene expression and/or protein expression profiles)) with clinical relevance to cytokine release syndrome (CRS).

公开(公告)号：US20240271215A1

公开(公告)日：2024-08-15

申请号：US18631414

申请日：2024-04-10

Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

Inventor： David A. Schwartz ,  Tasha E. Fingerlin ,  Weiming Zhang

IPC: C12Q1/6883 ,  G01N33/68

CPC classification number: C12Q1/6883 ,  G01N33/6893 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2800/12 ,  G01N2800/50 ,  G01N2800/52 ,  G01N2800/60

Abstract: Disclosed are biomarkers, methods and assay systems for the identification of poor prognosis of interstitial pneumonia (pulmonary fibrosis) in an individual diagnosed with suspected of having interstitial pneumonia.

公开(公告)号：US20240248101A1

公开(公告)日：2024-07-25

申请号：US18563663

申请日：2022-05-25

Applicant: Mark A. Levine ,  Ifechukwude C. Ebenuwa ,  Pierre-Christian Violet

Inventor： Mark A. Levine ,  Ifechukwude C. Ebenuwa ,  Pierre-Christian Violet

IPC: G01N33/82 ,  A61K31/375 ,  A61K45/06 ,  A61P13/12 ,  G01N30/02 ,  G01N30/64 ,  G01N30/88

CPC classification number: G01N33/82 ,  A61K31/375 ,  A61K45/06 ,  A61P13/12 ,  G01N30/64 ,  G01N30/88 ,  G01N2030/027 ,  G01N2030/8813 ,  G01N2800/042 ,  G01N2800/50 ,  G01N2800/52

Abstract: The invention provides a method involving assessing the vitamin C renal leak status of a human subject, vitamin C renal leak being the clinically inappropriate presence of vitamin C in urine. The method comprises assaying for the concentration of vitamin C in a plasma sample and in collected urine output, whereby the presence of vitamin C in the collected urine output and a concentration of vitamin C in the plasma sample less than the Minimum Elimination Threshold (MET) indicates the presence of vitamin C renal leak. Vitamin C renal leak also can be quantified by determining the fractional excretion of vitamin C (FeVC), which is a measurement of the degree of urinary vitamin C excretion relative to plasma vitamin C concentration corrected by creatinine clearance. The invention also provides a test kit for assessing vitamin C renal leak and a test kit for assessing FeVC.

公开(公告)号：US20240241132A1

公开(公告)日：2024-07-18

申请号：US18420177

申请日：2024-01-23

Applicant: The Trustees of the University of Pennsylvania

Inventor： Mark I. Greene ,  Douglas B. Cines ,  Zheng Cai ,  Zhiqiang Zhu

IPC: G01N33/68 ,  A61K38/19 ,  A61K39/395 ,  C07K14/52 ,  C07K16/24 ,  G01N33/86 ,  A61K39/00

CPC classification number: G01N33/6863 ,  A61K38/195 ,  A61K39/3955 ,  C07K14/522 ,  C07K16/24 ,  G01N33/86 ,  A61K2039/505 ,  G01N2333/522 ,  G01N2400/40 ,  G01N2800/222 ,  G01N2800/50 ,  G01N2800/52

Abstract: The present invention provides a mutant protein which has the same amino acid sequence of a wild type PF4 monomer except that (i) at least one amino acid of the wild type PF4 monomer has been deleted, (ii) at least one amino acid of the wild type PF4 monomer has been replaced by another amino acid, or (iii) a combination of such changes has been made. The present invention also provides methods of treating or reducing the likelihood of HIT, treating angiogenesis, treating abnormal cell growth, or affecting coagulation pathologies that lead to thrombus formation, by administering such mutant proteins to a patient.

公开(公告)号：US20240230676A1

公开(公告)日：2024-07-11

申请号：US18558150

申请日：2022-04-29

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Felix Gruenewald ,  Victor Johann Raul Jeger ,  Martin Klammer ,  Philipp Schuetz ,  Maria von Holtey ,  Stephen Weber ,  Heike Wegmeyer ,  Ursula-Henrike Wienhues-Thelen

IPC: G01N33/68 ,  C12Q1/37 ,  C12Q1/52 ,  G01N33/72 ,  G16H50/20

CPC classification number: G01N33/6893 ,  C12Q1/37 ,  C12Q1/52 ,  G01N33/728 ,  G16H50/20 ,  G01N2333/4722 ,  G01N2333/8139 ,  G01N2333/91188 ,  G01N2800/26 ,  G01N2800/50

Abstract: The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being ESM-1, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is Creatinine or a Cystatin C, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being ESM-1 and a second biomarker being Creatinine or a Cystatin C or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.